Molecular Profiling and Classification of Sporadic Renal Cell Carcinoma by Quantitative Methylation Analysis

Mark L. Gonzalgo,  
Srinivasan Veygasubramanian, Gai Yan,  
Craig G. Rogers, Theresa L. Nicol,  
William G. Nelson, and Christian P. Pavlovich  
The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland

ABSTRACT

Purpose: Preoperative histologic classification of solid renal masses remains limited with current technology. We determine the utility of molecular profiling based on quantitative methylation analysis for characterization of sporadic renal cell carcinoma.

Experimental Design: Primary renal cell carcinomas representing three different histologic subtypes were obtained from a total of 38 patients who underwent radical nephrectomy for suspected malignant disease. Genomic DNA was isolated from tumors and was subjected to sodium bisulfite modification. The normalized index of methylation (NIM) for each sample was determined by quantitative real-time methylation-specific PCR at 17 different gene promoters. Hierarchical cluster analysis was performed by using an unsupervised neural network with binary tree topology.

Results: The majority of gene promoters that were analyzed in this study demonstrated very low levels of methylation (NIM < 1.0). The RASSFIA gene promoter, however, was methylated in 30 of 38 (79%) cases. The frequency of RASSFIA methylation in papillary, clear-cell, and oncocytomas subtypes was 100, 90, and 25%, respectively. The highest levels of RASSFIA methylation were observed in the papillary (mean NIM = 78.9) and clear-cell (mean NIM = 13.4) subtypes. The vast majority of oncocytomas were completely unmethylated, and none demonstrated >1% methylation (mean NIM = 0.11). Hierarchical cluster analysis based on quantitative methylation levels resulted in stratification of sporadic renal cell carcinomas into their discrete histologic subtypes.

Conclusions: Classification of sporadic renal cell carcinomas into histologic subtypes can be accomplished via multigene quantitative methylation profiling. Validation of this approach and selection of appropriate methylation markers may ultimately lead to use of this technology in the preoperative assessment of suspicious renal masses.

INTRODUCTION

It is estimated that 35,710 new cases of renal cancer will be diagnosed and 12,480 people will die of the disease in the year 2004 (1). Renal cell carcinoma (RCC) consists of a heterogeneous group of epithelial tumors that range in biological potential from entirely benign to aggressively malignant (2, 3). Clear-cell carcinoma is the most common subtype of RCC, accounting for 70 to 80% of all renal epithelial tumors (4). Papillary carcinoma is the second most frequent RCC variant and comprises approximately 10 to 15% of renal tumors. Renal oncocytomas are considered benign and are next most common in prevalence, accounting for 3 to 7% of renal tumors (5). At the present time, relatively few preoperative predictors of malignancy or histologic subtype exist in clinical practice. Present diagnostic imaging modalities cannot always differentiate between benign and malignant solid renal masses, and, as a result, the treatment of choice for all suspicious renal masses is surgical removal. Therefore, it would be of great benefit to identify molecular markers that could distinguish benign from malignant disease.

A large number of cytogenetic alterations have been described for the different histologic RCC subtypes, which have, in turn, allowed for modern classification systems for renal epithelial tumors (2, 6, 7). Clear-cell RCC is characterized by VHL (3p25) mutations and/or inactivation, chromosome 3p loss, and 5q gain (8, 9). Trisomy of chromosomes 7 and 17 is common in papillary RCC, and abnormalities of chromosomes 12, 16, 20, and Y, as well as c-MET mutations (7q31) are also occasionally found in such tumors (6, 10). Loss of chromosomes 1 and Y, loss of heterozygosity at 14q, and abnormalities involving 1q13 have been reported for oncocytomas, although many oncocytomas have no obvious cytogenetic abnormalities (6, 11). Modern RCC classification systems take into account cytogenetic, molecular genetic, and histologic differences between RCC tumor subtypes and have been validated by these findings.

A molecular marker that has only recently been investigated in renal cancers is aberrant DNA methylation. Methylation at cytosines located at CpG dinucleotides is a ubiquitous but regulated phenomenon essential for normal mammalian development (12). Hypermethylation of CpG islands in the promoter regions of genes is associated with transcriptional silencing and is a frequent event in human cancer (13). We sought to determine the methylation profiles of 38 sporadic renal cancers at 17 gene loci and assess the utility of quantitative multigene DNA methylation analysis for stratification of RCC subtypes.
MATERIALS AND METHODS

Patients and Specimen Collection. A total of 38 patients who were treated with radical or partial nephrectomy for suspected renal malignancy were selected for this study. All of the patients provided informed consent for use of tissues, and this protocol was approved by The Johns Hopkins University School of Medicine Institutional Review Board (IRB). Normal kidney tissue was obtained from nephrectomy specimens at a location that was distant from the area of tumor involvement. Normal and tumor kidney tissues were snap-frozen and stored at −70°C before analysis.

DNA Isolation, Bisulfite Modification, and Real-time Methylation-Specific PCR. Total DNA was extracted from kidney tissues and 1 μg was subjected to sodium bisulfite modification with the CpGenome DNA Modification kit (Sero-logicals Co., Norcross, GA). Real-time methylation-specific PCR (RT-MSP) was performed with a technique based on the principle of the MethLight assay (14). Bisulfite-modified DNA was amplified with real-time PCR with primers and probes complementary to a region of the MYOD1 promoter that did not contain any CpG dinucleotides but did contain non-CpG cytosines, to ascertain the amount of converted templates at the promoter of interest to the amount of methylated templates at the promoter of interest to the amount of converted DNA was amplified with real-time PCR with primers and Taqman probes specific for fully methylated bisulfite-converted sequences.

The primer and probe sequences used for this study are listed in Table 1. All PCR reactions were carried out on an iCycler real-time thermal cycler (Bio-Rad, Hercules, CA) at 95°C for 10 minutes, followed by 25 cycles of 95°C for 15 seconds, 60°C for 30 seconds, and 72°C for 30 seconds. The EDNRB reaction was carried out under the same conditions, except that an annealing temperature of 64.5°C was used. Each PCR reaction was carried out in a 25-μL volume containing 2.5 μL of 10× PCR buffer; 1 unit of AmpliTaq Gold (Applied Biosystems, Foster City, CA); 2.5 mmol/L forward primer; 2.5 mmol/L reverse primer; 200 mmol/L Taqman probe; 0.25 mmol/L concentration of dATP, dCTP, dTP, and dGTP; 5.5 mmol/L MgCl₂; and 1 μL template DNA. Bisulfite-converted SsII-treated white blood cell DNA served as a positive control and was used to generate a standard curve to quantify the amount of fully methylated alleles in each reaction. Bisulfite-converted white blood cell DNA from normal volunteers and blank reactions with water substituted for DNA served as negative controls. All PCR reactions for each locus and sample examined were performed in triplicate, and the mean quantitative methylation level was recorded. The normalized index of methylation (NIM) was defined as the ratio of the amount of methylated templates at the promoter of interest to the amount of converted MYOD1 templates in any given sample. The NIM serves as an index of the percentage of input copies of DNA that are fully methylated at the primer- and probe-binding sites.

Bisulfite Genomic Sequencing of the RASSF1A Gene. Bisulfite genomic sequencing of RASSF1A was performed as described previously (15, 16). Briefly, 25 ng of bisulfite-converted DNA was mixed with 2.5 μL of 10× PCR Buffer II, 1.25 units AmpliTaq Gold, 0.5 mmol/L primers (forward: 5'-GTGTTTTGATGTTTTAGTGG-3', reverse: 5'-ACCTCTCTTCTCTTAAACAACTAAACC-3'), 200 mmol/L concentration of each dNTP, and 5 mmol/L MgCl₂, in a total reaction volume of 25 μL. PCR amplification was carried out at 95°C for 10 minutes, followed by 25 cycles of 95°C for 15 seconds, 55°C for 15 seconds, and 74°C for 30 seconds, and ended with a 6-minute extension at 74°C. PCR products were purified with the QiAquick PCR Purification kit (Qiagen, Valencia, CA). Approximately 1 to 2 μL of the purified DNA solution was amplified in a semi-nested PCR under similar conditions for 30 cycles, with each cycle consisting of 95°C for 30 seconds, 55°C for 30 seconds, and 74°C for 1 minute. The

Table 1 Primers and Taqman probes used for all loci in this study

<table>
<thead>
<tr>
<th>HUGO gene name</th>
<th>5' to 3' forward primer</th>
<th>5' to 3' reverse primer</th>
</tr>
</thead>
<tbody>
<tr>
<td>RASSF1A</td>
<td>GCCGTGAACTGCGGGTTC</td>
<td>GGCGTTCGTTTTGGGATTG</td>
</tr>
<tr>
<td>CDH1</td>
<td>AATTGTAGTTAGGTTATCCTC</td>
<td>TACCTGTTATGCTGTTATCTC</td>
</tr>
<tr>
<td>MLH1</td>
<td>CTATCCGCCCTCTATCCT</td>
<td>TATCCGCTATCCTATCCCT</td>
</tr>
<tr>
<td>BHD</td>
<td>CGTTATCTCGGATATTTGTCG</td>
<td>GTGTTATGCTGCTGTTATCC</td>
</tr>
<tr>
<td>VHL</td>
<td>TCGGAGATTTTTTCTGCAAGC</td>
<td>GCCTGGAAGTCGGTTACGTG</td>
</tr>
<tr>
<td>INK4a/arf</td>
<td>ACCGGCTTTGCTTGATTG</td>
<td>ACCGGCTTTGCTTGATTG</td>
</tr>
<tr>
<td>PTGS2</td>
<td>CGGAAAGGGTGGTCTGAAAG</td>
<td>CGGAAAGGGTGGGCTTCAAG</td>
</tr>
<tr>
<td>EDNRB</td>
<td>CCTCAACTGCTCCGCAAGGAAAGAAATGTTG</td>
<td>ATACCCCGCTCCTATCCCTAGC</td>
</tr>
<tr>
<td>MDR1</td>
<td>CGGGCGTAACTGCAAGCAGC</td>
<td>CAGAGGCGTAACTGCAAGCAGC</td>
</tr>
<tr>
<td>TIMP3</td>
<td>AGTCGCGAGTTATGAGGTTG</td>
<td>GTCGCGAGTTATGAGGTTG</td>
</tr>
<tr>
<td>CDKN2a</td>
<td>CGGGTTGCTTGCTTGATTG</td>
<td>GGGTTGCTTGCTTGATTG</td>
</tr>
<tr>
<td>CDKN2B</td>
<td>AGGAGGAGAGGAGAGTCG</td>
<td>AGGAGGAGAGGAGAGTCG</td>
</tr>
<tr>
<td>APC</td>
<td>TTTATGTTGCTGTGATCTTATAT</td>
<td>CCGCCCTCTCTCTCTCTCTCT</td>
</tr>
<tr>
<td>GSTP1</td>
<td>AGTTCGCGGCGATTCCTC</td>
<td>CGGCGGCGGCGGCGGCGGCGG</td>
</tr>
<tr>
<td>MGMT</td>
<td>GGGTGTCGAGGTGCAGTGGT</td>
<td>GGGTGTCGAGGTGCAGTGGT</td>
</tr>
<tr>
<td>DAPK</td>
<td>GGGATGCGGATGCTGATGATGCTC</td>
<td>GGGATGCGGATGCTGATGATGCTC</td>
</tr>
<tr>
<td>ESRI</td>
<td>GCGCGCTTCGTTGGATTTG</td>
<td>GCGCGCTTCGTTGGATTTG</td>
</tr>
<tr>
<td>MYOD1</td>
<td>CCAACTCTAAATCTTCCCTCCTAT</td>
<td>CCAACTCTAAATCTTCCCTCCTAT</td>
</tr>
</tbody>
</table>

NOTE. Sequences listed are specific for sodium bisulfite-converted DNA. Primers and probes for the MYOD1 locus do not contain any CpG dinucleotides, making this primer set insensitive to methylation and appropriate as a conversion control.

Abbreviations: HUGO, Human Genome Organization nomenclature; 6FAM, 6-carboxyfluorescein; BHQ1, 3′ quencher.
inner primer set sequences were 5'-TAATGAGTTAGGT-TTTTTYGATATGGT-3' (forward) and 5'-AACACAATAA-AACTAACCCTCCAAAAAC-3' (reverse). PCR products were gel-purified (QIAquick Gel Extraction kit, Qiagen), then cloned into the pCR4-TOPO vector (TOPO TA Cloning kit, Invitrogen, Carlsbad, CA). After transformation, 10 colonies per specimen were expanded overnight and plasmid DNA was extracted (QIAprep Spin Miniprep kit, Qiagen). Sequencing was performed by the DNA Analysis Facility at the Johns Hopkins University Medical Institution (Baltimore, MD).

**Hierarchical Clustering of Sporadic Renal Cell Carcinoma According to CpG Island Promoter Hypermethylation.** Cluster analysis was performed in a blinded manner with the self-organizing hierarchical neural network SOTA (self-organizing tree algorithm), an unsupervised neural network with a binary tree topology (17). An unrestricted growth algorithm was used to generate a dendrogram for classification of tumor subtypes based on data obtained from quantitative real-time PCR analyses. The TREEVIEW program was used to visualize the out file as a binary tree (19). Matrix values were transformed into a graded color pattern representing the level of methylation for each point of the matrix (see Fig. 1). Application of hierarchical clustering algorithms to methylation data has been previously validated (18, 19).

**Statistical Analysis.** The mean NIM and exact binomial 95% confidence intervals were calculated for each gene locus and tumor type. The association between RASSF1A promoter methylation and clinical/pathologic characteristics was examined with two-sided, Fisher’s exact test. All analyses were performed with STATA 7.0 (Stata Corporation, College Station, TX).

**RESULTS**

We analyzed DNA obtained from nephrectomy specimens of 38 patients for the presence of gene methylation. Distinct CpG islands associated with 17 gene promoters were examined (see Table 1). The loci were chosen based on their established relevance to various human cancers and, specifically, renal cell carcinoma, as reported in the literature (20–24). The clinical and pathologic characteristics of our study group are shown in Table 2. Sufficient DNA was obtained from all 38 tumor specimens to generate PCR products after sodium bisulfite modification.

Methylation analysis was performed with fluorescence-based, RT-MSP (14). Results from a typical PCR analysis of renal tumors at one gene locus (RASSF1A) are shown in Fig. 1. Papillary tumors frequently demonstrated higher levels of RASSF1A methylation compared with clear-cell carcinomas or oncocytomas as indicated by a lower threshold cycle. Each primer pair and corresponding probe was designed to evaluate the methylation status of 6 to 11 CpG dinucleotides for each gene promoter that was examined. On average, 9 CpG dinucleotides were sampled by each primer and probe set. Hybridization of primers and probes is contingent on the presence of a high degree of methylation at CpG sites in the region of oligonucleotide hybridization. Thus, the primer and probe sets were designed for the highest level of methylation specificity. Possible explanations for a negative result include: partial methylation, no methylation, or absence of the region of interest area (i.e., homozygous deletion).

**Hierarchical Clustering of Renal Tumors on the Basis of DNA Methylation.** Results from RT-MSP analysis of 38 renal tumors (21 clear-cell RCC, 9 papillary RCC, and 8 oncocytomas) are shown in Fig. 2A. The NIM color scale ranges from 0 to 100. A dendrogram representing the classification of tumor subtypes based on methylation status is shown in Fig. 2B. The results indicate a significant difference in methylation profile between papillary and clear-cell tumors.

**Table 2**

| No. of patients | 38 |
| Males, N (%) | 28 (73.7) |
| Females, N (%) | 10 (26.3) |
| Mean, age ± SD | 61.1 ± 13.3 |
| Tumor size, N (%) | |
| <4.0 cm | 13 (34.2) |
| ≥4.0 cm | 25 (65.8) |
| Pathologic stage, N (%) | |
| T1 | 19 (50.0) |
| T2 | 10 (26.3) |
| ≥T3 | 9 (23.7) |
| Furhman grade, N (%) | |
| I–II | 23 (60.5) |
| > II | 15 (39.5) |
from white (<1% methylation) to black (>50% methylation) for each sample analyzed. Cluster analysis based on NIM values for each gene and tumor was performed in a blinded manner with a self-organizing tree algorithm (17). The dendrogram generated from an unrestricted growth algorithm for classification of tumor subtypes is shown to the left of Fig. 2A. The remarkable finding of this experiment was that CpG island hypermethylation alone allowed for classification of most of the renal tumors according to their histologic subtype. A total of 7 (78%) of 9 papillary RCCs clustered into an independent primary branch from the other histologic subtypes of renal tumors. A total of 20 (91%) of 21 clear-cell RCCs and 8 (100%) of 8 oncocytomas shared the same primary branch that was separate from papillary RCCs. An additional distinction between clear-cell RCCs and oncocytomas was observed; 6 (75%) of 8 oncocytomas clustered into an independent terminal branch. Although it is apparent that the clustering algorithm was predominantly influenced by the degree of RASSF1A methylation, our findings represent the first evidence that DNA methylation can potentially be used as a molecular marker for the stratification of renal tumors into discrete histologic subtypes.

**Frequency and Level of Gene Hypermethylation in Renal Tumors.** High levels of RASSF1A promoter methylation were frequently detected in papillary and clear-cell RCCs compared with oncocytomas (see Figs. 1 and 2). Methylation of RASSF1A was detected in a total of 9 (100%) of 9 papillary RCCs and 19 (90%) of 21 clear-cell RCCs. The mean NIM was 78.9 [95% confidence interval (CI), 43.1–114.7] for papillary RCCs and 13.4 (95% CI, 6.2–20.6) for clear-cell RCCs. In contrast, no significant methylation of RASSF1A was detected in the eight oncocytomas that were examined. Two oncocytomas had extremely low levels of methylation (<1%) as demonstrated by the mean NIM value of 0.11, which was ~720-fold and 120-fold lower than papillary and clear-cell RCCs, respec-

---

**Fig. 2** Methylation profile of sporadic RCCs. **A**, at left, dendrogram generated from hierarchical cluster analysis; color scale at the bottom left, methylation levels; at the top of the figure, the 17 genes analyzed for methylation; on the right side of the matrix, histologic tumor subtype, clustered based on hierarchical analysis. **B**, frequency and mean NIM of certain genes stratified according to RCC subtype; white columns, frequency of methylation (%); black columns, mean NIM for each gene.
tively. Other genes were frequently methylated in renal tumors, albeit at low levels, and included: PTGS2, EDNRB, APC, and ESR1. The frequency and mean NIM for each of these genes stratified according to histologic subtype is shown in Fig. 2B.

Frequency and Level of Gene Hypermethylation in Normal Kidney and Renal Tumor Pairs. Results from RT-MSP analysis of RASSF1A, PTGS2, EDNRB, APC, and VHL among 22 normal kidney and tumor pairs (6 papillary RCCs, 14 clear-cell RCCs, and 2 oncocytomas) are shown in Fig. 3A. Interestingly, we found that neighboring normal kidney tissue was frequently methylated at low levels in some genes. A total of 20 (91%) of 22 normal renal tissue specimens had detectable RASSF1A methylation. Fig. 3B shows the frequency and mean NIM for normal kidney, papillary RCC, clear-cell RCC, and oncocytoma, stratified according to certain genes that were studied (RASSF1A, PTGS2, EDNRB, and APC). The mean NIM level of RASSF1A in normal kidney was 13.5 (95% CI: 9.5–17.5). The frequency and mean NIM of RASSF1A in the corresponding paired papillary RCCs, clear-cell RCCs, and oncocytomas was 100% (mean NIM = 60.8), 86% (mean NIM = 12.8), and 50% (mean NIM = 0.09), respectively.

Bisulfite Genomic Sequencing of the RASSF1A Gene Locus. We performed bisulfite genomic sequencing of the RASSF1A gene locus to determine the exact nature of methylation patterns that existed in all three tumor subtypes and normal kidney (see Fig. 4). Papillary tumors demonstrated higher levels of methylation compared with clear-cell tumors or oncocytomas. There was an excellent correlation between results ob-

![Fig. 3](image-url) Methylation profile of normal and tumor kidney pairs. A, methylation profiles of 5 genes; color scale at the bottom left, methylation levels; on the right side of the matrix, histologic tumor subtype, clustered based on hierarchical analysis; N, normal; T, tumor. B, frequency and mean NIM for normal kidney, papillary RCC, clear-cell RCC, and oncocytoma, stratified according to gene locus; white columns, frequency of gene methylation (%); black columns, mean NIM for each gene.
tained by bisulfite sequencing and the region analyzed by RT-MSP for each tumor subtype. Bisulfite sequencing also confirmed the presence of a low degree of methylation in normal kidney as observed by the real-time quantitative PCR data and the work of others (25). These results provide further validation of the RT-MSP methodology used in our experiments and previously published work (14, 18, 20, 21, 26).

**Relationship between RASSF1A Methylation and Clinical/Pathologic Variables.** We determined whether RASSF1A methylation was associated with certain clinical or pathological variables (see Table 3). NIM values for each tumor were stratified into one of four groups depending on the level of RASSF1A methylation (0–10%, 11–25%, 26–50%, >50%). Higher levels of methylation (NIM >50%) were associated with ≥T2 pathological stage of disease (P = 0.04). There were no other statistically significant associations between RASSF1A methylation and the remaining clinical or pathologic variables analyzed (i.e., age, tumor size, Fuhrman grade). Significantly more oncocytomas were found to have absent or low levels of RASSF1A methylation (NIM <10%) compared with papillary RCCs (P < 0.001) and clear-cell RCCs (P = 0.03). Clear-cell RCCs were also more frequently observed to have low levels of methylation (NIM <10%) compared with papillary tumors (P = 0.04). More papillary RCCs had higher levels of RASSF1A methylation (>50%) compared with clear-cell RCCs (P < 0.001) and oncocytomas (P = 0.002). These findings underscore the differences in RASSF1A methylation between tumor subtypes and support our data generated from hierarchical cluster analysis.

**DISCUSSION**

We have demonstrated for the first time that quantitative gene methylation profiling can be used to stratify RCCs into distinct histologic subtypes. The dendrogram generated from hierarchical cluster analysis (see Fig. 2A) indicates that papillary RCCs have significantly different patterns of gene methylation compared with clear-cell RCCs and oncocytomas. Although clear-cell RCCs appeared to be more closely related to oncocytomas than to papillary RCCs, 75% of oncocytomas clustered into an independent terminal branch. Furthermore, statistical analyses examining the relationship between RASSF1A methylation and renal tumors demonstrated concordant results with respect to the relatedness of the three histologic subtypes (see Table 3). Papillary RCCs were more frequently observed to have higher levels of RASSF1A methylation (>50%) compared with oncocytomas (P = 0.002) and clear-cell RCCs (P <
Methylation Profile of Sporadic Renal Cell Cancer

...of the remaining normal RASSF1A allele may account for the “two-hits” needed for complete inactivation of this candidate tumor suppressor gene. We found a high frequency of RASSF1A methylation in both papillary (100%) and clear-cell (90%) RCCs (see Fig. 2). However, the mean NIM was significantly higher for papillary RCCs compared with clear-cell RCCs (78.9 versus 13.4%; see Fig. 2B). It is plausible that these findings indicate frequent bi-allelic inactivation of RASSF1A by DNA methylation is characteristic of papillary RCCs, whereas clear-cell RCCs may have already lost a copy of the gene and, therefore, only have one remaining allele that can become hypermethylated. Our results support the hypothesis that epigenetic inactivation of RASSF1A by promoter methylation represents a critical step in the pathogenesis of both papillary and clear-cell RCCs as suggested by others (32).

In conclusion, development of novel molecular methods to characterize renal tumors is of paramount importance because most renal oncocytomas cannot be differentiated from malignant RCCs based on clinical or radiographic findings. We demonstrate for the first time that molecular profiling of renal tumors by quantitative methylation analysis can be used to distinguish between histologic subtypes of RCC. The candidate tumor suppressor gene RASSF1A was frequently methylated in papillary and clear-cell RCCs, but not in oncocytomas. Additional studies investigating the utility of DNA methylation for disease stratification and prognostication are warranted. Validation of this approach and selection of appropriate methylation markers may ultimately lead to use of this technology in the preoperative assessment of suspicious renal masses.

REFERENCES

Molecular Profiling and Classification of Sporadic Renal Cell Carcinoma by Quantitative Methylation Analysis

Mark L. Gonzalgo, Srinivasan Yegnasubramanian, Gai Yan, et al.


**Updated version**
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/10/21/7276

**Cited articles**
This article cites 28 articles, 10 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/10/21/7276.full#ref-list-1

**Citing articles**
This article has been cited by 4 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/10/21/7276.full#related-urls

**E-mail alerts**
Sign up to receive free email-alerts related to this article or journal.

**Reprints and Subscriptions**
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

**Permissions**
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.